Codexis, Inc. (NASDAQ:CDXS) Director Thomas R. Baruch sold 17,500 shares of the stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $15.61, for a total transaction of $273,175.00. Following the completion of the sale, the director now owns 90,540 shares of the company’s stock, valued at approximately $1,413,329.40. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
Shares of CDXS opened at $15.81 on Friday. The company’s fifty day moving average is $14.91 and its 200-day moving average is $15.70. Codexis, Inc. has a 12 month low of $12.68 and a 12 month high of $22.49. The firm has a market cap of $911.71 million, a price-to-earnings ratio of -75.29 and a beta of -0.01. The company has a quick ratio of 7.34, a current ratio of 7.37 and a debt-to-equity ratio of 0.25.
Codexis (NASDAQ:CDXS) last announced its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported $0.01 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.09) by $0.10. Codexis had a negative net margin of 17.85% and a negative return on equity of 15.24%. The company had revenue of $21.91 million for the quarter, compared to analyst estimates of $16.56 million. As a group, research analysts predict that Codexis, Inc. will post -0.2 earnings per share for the current fiscal year.
A number of large investors have recently bought and sold shares of the stock. Capital Investment Advisory Services LLC acquired a new stake in Codexis in the 2nd quarter worth $37,000. Tower Research Capital LLC TRC bought a new position in Codexis during the 2nd quarter valued at about $41,000. Quantamental Technologies LLC bought a new position in Codexis during the 2nd quarter valued at about $44,000. Aperio Group LLC bought a new position in Codexis during the 2nd quarter valued at about $98,000. Finally, SG Americas Securities LLC bought a new position in Codexis during the 2nd quarter valued at about $190,000. Institutional investors and hedge funds own 89.40% of the company’s stock.
A number of equities research analysts have issued reports on CDXS shares. BidaskClub upgraded shares of Codexis from a “strong sell” rating to a “sell” rating in a research report on Wednesday. Zacks Investment Research downgraded shares of Codexis from a “strong-buy” rating to a “hold” rating in a research report on Thursday, November 14th. One analyst has rated the stock with a sell rating, one has given a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $20.50.
Codexis Company Profile
Codexis, Inc discovers, develops, and sells protein catalysts. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services.
Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.